Sign up


Match Document Document Title
8969317 MicroRNA compounds and methods for modulating miR-21 activity  
Described herein are compositions and methods for the inhibition of miR-21 activity. The compositions have certain nucleoside modification patterns that yield potent inhibitors of miR-21 activity....
8969316 Compounds and methods for modulating expression of DGAT2  
The present disclosure describes short antisense compounds, including such compounds comprising chemically-modified high-affinity monomers 8-16 monomers in length. Certain such short antisense...
8969318 Bispecific aptamers mediating tumour cell lysis  
Disclosed are bispecific aptamers binding with high specifity to a tumour specific antigen (TSA) and a effector cell specific antigen (ESA) for treatment of cancer.
8969314 Methods for use in modulating miR-122a  
Methods are provided for the treatment of cardiovascular or metabolic diseases characterized by elevated serum total cholesterol, elevated serum LDL-cholesterol, or elevated serum triglycerides,...
8962585 Treatment of tumor protein 63 (p63) related diseases by inhibition of natural antisense transcript to p63  
The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Tumor Protein 63 (p63), in particular, by targeting natural antisense polynucleotides...
8962592 Methods of treating a meiotic kinesin associated disease  
The invention provides methods of treating a meiotic kinase-associated disease, preferably the meiotic kinase HSET, by administering an inhibitor of the meiotic kinase. Preferably, the disease is...
8962584 Compositions for controlling Varroa mites in bees  
An isolated nucleic acid agent is disclosed comprising a nucleic acid sequence which downregulates expression of a gene product of a Varroa destructor mite. Compositions comprising same and uses...
8962588 Micro-RNAS that control myosin expression and myofiber identity  
The present invention relates to the identification of two microRNAs, miR-499 and miR-208b, that repress fast skeletal muscle contractile protein genes. Expression of miR-499 and/or miR-208b can be...
8962586 Treatment of pyrroline-5-carboxylate reductase 1 (PYCR1) related diseases by inhibition of natural antisense transcript to PYCR1  
The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Pyrroline-5-carboxylate reductase 1 (PYCR1), in particular, by targeting natural...
8962582 PKR activation via hybridization chain reaction  
The present application relates to the use of hybridization chain reaction (HCR) to form double stranded RNA polymers in the presence of a target, such as a nucleic acid associated with a disease...
8962757 Graft polymers for enhanced intracellular delivery of antisense molecules  
Innovative graft polymers designed for the efficient delivery of antisense molecules into biological cells and for maintaining the biological activity of these molecules while in serum and other...
8957037 Treatment of reprogramming factor related diseases by inhibition of natural antisense transcript to a reprogramming factor  
The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of a Reprogramming factor, in particular, by targeting natural antisense polynucleotides...
8957012 Gamma secretase inhibitor for treatment of herpesvirus infection  
This invention relates to methods and compositions for the treatment of malignancies associated with gamma-herpesvirus infection. Specifically, the invention relates to the use of gamma-secretase...
8957039 Methods and compositions for the diagnosis and prognosis of cervical intraepithelial neoplasia and cervical cancer  
The invention provides methods and compositions for the diagnosis and prognosis of cervical intraepithelial neoplasia and cervical cancer. The methods comprise the step of determining the...
8957041 Short interfering ribonucleic acid (siRNA) for oral administration  
Short interfering ribonucleic acid (siRNA) for oral administration, said siRNA comprising two separate RNA strands that are complementary to each other over at least 15 nucleotides, wherein each...
8957040 Selective reduction of allelic variants  
Disclosed herein are antisense compounds and methods for selectively of reducing expression of an allelic variant of a gene containing a single nucleotide polymorphism (SNP). Such methods,...
8957191 Nucleic acid comprising zwitterionic nucleotides  
This invention provides pH-responsive zwitterionic nucleotides and nucleic acids comprising said nucleotides, wherein said zwitterions are constituted from one or more anionic internucleoside...
8957038 Treatment of neurological disorders  
This invention provides treatment compositions as well as systems and methods of determining and administering an effective amount of treatment for a neurological disorder. The treatment...
8957199 Oligoribonucleotide or peptide nucleic acid capable of inhibiting activity of hepatitis C virus  
The present inventors focused on siE sequences that have been thought to show RNAi activity against HCV viral RNAs, and mainly selected the D5-50 and D5-197 regions present within the IRES region,...
8951979 Pain treatment using ERK2 inhibitors  
This application describes methods and compositions for reducing, inhibiting and/or treating pain that involve use of ERK2 inhibitors.
8951984 Oligonucleotides for modulation of target RNA activity  
The present invention relates to oligonucleotides for modulation of target RNA activity. Thus, the invention provides oligonucleotides that bind to microRNA binding sites of target RNA. The...
8951527 Radioprotectants targeting thrombospondin-1 and CD47  
Described herein is the discovery that cell and tissue survival can be dramatically increased following radiation exposure through inhibition of the interaction between TSP-1 and CD47. This effect...
8951982 Methods and compositions for the treatment of eye disorders with increased intraocular pressure  
The present invention relates to methods and compositions that decrease intraocular pressure (IOP) of the eye. The compositions of the invention comprise short interfering nucleic acid molecules...
8951981 Treatment of paraoxonase 1 (PON1) related diseases by inhibition of natural antisense transcript to PON1  
The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Paraoxonase 1(PON1), in particular, by targeting natural antisense polynucleotides of...
8946185 Agent for suppressing expression of dominant allele  
An agent for selectively suppressing the expression of a dominant allele while allowing expression of wild-type or desired alleles and methods for using the agent are described. The RNAi agent has...
8946170 Sustained release siRNA for ocular drug delivery  
An ocular implant comprising siRNA complexed with a transfection agent selected from the group consisting of cationic lipids and short cell penetration peptides, wherein the complex is associated...
8946181 Treatment of interferon regulatory factor 8 (IRF8) related diseases by inhibition of natural antisense transcript to IRF8  
The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Interferon Regulatory Factor 8 (IRF8), in particular, by targeting natural antisense...
8946186 QSOX1 as an anti-neoplastic drug target  
The present invention provides methods for tumor treatment by administering an inhibitor of quiescin sulfhydryl oxidase 1 (QSOX1), compositions comprising such inhibitors, and methods for...
8946177 Methods and compositions involving miRNA and miRNA inhibitor molecules  
The present invention concerns methods and compositions for introducing miRNA activity or function into cells using synthetic nucleic acid molecules. Moreover, the present invention concerns...
8946184 Aptamer therapeutics useful in the treatment of complement-related disorders  
The invention provides nucleic acid therapeutics and methods for using these nucleic acid therapeutics in the treatment of complement-related disorders.
8946180 Means and methods for the specific modulation of target genes in the CNS and the eye and methods for their identification  
Provided are methods for the treatment of disorders of the central nervous system (CNS) and the eye. In particular, use of compositions comprising a compound capable of modulating a target gene or...
8946182 Treatment of RNASE H1 related diseases by inhibition of natural antisense transcript to RNASE H1  
The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of RNase H1, in particular, by targeting natural antisense polynucleotides of RNase H1....
8946179 Oligomeric compounds and compositions for use in modulation of small non-coding RNAs  
Compounds, compositions and methods are provided for modulating the expression and function of small non-coding RNAs. The compositions comprise oligomeric compounds, targeted to small non-coding...
8946176 Compositions and methods for inhibiting expression of RRM2 genes  
The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of a RRM2 gene. The invention also relates to a pharmaceutical composition comprising the dsRNA or...
8946178 Compositions and methods for treatment of pouchitis  
The present invention relates methods of treating pouchitis by administering a pharmaceutical formulation suitable for rectal use, such as an enema or suppository, comprising an antisense...
8940712 Micro-RNA family that modulates fibrosis and uses thereof  
The present invention relates to the identification of a microRNA family, designated miR-29a-c, that is a key regulator of fibrosis in cardiac tissue. The inventors show that members of the miR-29...
8940683 Localized therapy of lower airways inflammatory disorders with proinflammatory cytokine inhibitors  
The present invention is drawn to methods and compositions for treating inflammatory disorders of the lower airways, comprising administering an effective amount of an agent, which modulates the...
8940713 Micro-RNA family that modulates fibrosis and uses thereof  
The present invention relates to the identification of a microRNA family, designated miR-29a-c, that is a key regulator of fibrosis in cardiac tissue. The inventors show that members of the miR-29...
8940709 Therapeutic alteration of transplantable tissues through in situ or ex vivo exposure to RNA interference molecules  
The present invention, at least in part, relates to the discovery of efficacious delivery of an RNAi agent (in preferred aspects of the invention, an siRNA) to a transplantable tissue. Organ...
8940299 Method of treating cancer  
A method for inducing apoptosis of a neoplastic cell expressing C3aR or C5aR includes administering at least one complement antagonist to the cell so that the at least one complement antagonist...
8940711 Micro-RNA family that modulates fibrosis and uses thereof  
The present invention relates to the identification of a microRNA family, designated miR-29a-c, that is a key regulator of fibrosis in cardiac tissue. The inventors show that members of the miR-29...
8940708 Treatment of hepatocyte growth factor (HGF) related diseases by inhibition of natural antisense transcript to HGF  
The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Hepatocyte Growth Factor (HGF), in particular, by targeting natural antisense...
8936910 Method for selective oligonucleotide modification  
Method for producing a modified oligonucleotide, wherein at least one polymer, preferably polyalkylene oxide, and/or a compound is covalently bound to the 5′-end or the 3′-end of the oli...
8936942 Polyethyleneglycol-modified lipid compounds and uses thereof  
The present invention provides compositions comprising polytheylyene-dialkyloxypropyl conjugates (PEG-DAA), liposomes, SNALP, and SPLP comprising such compositions, and methods of using such...
8933045 Modulation of human cytomegalovirus replication by micro-RNA 132 (miR132), micro-RNA 145 (mi145) and micro-RNA 212 (miR212)  
The present invention related to miR145, miR132, miR212, and the genes or gene products regulated by these miRNAs. miR145 is downregulated in cells infected with HCMV. This downregulation modulates...
8933042 Methods for controlling pests using RNAi  
The present invention relates to methods for controlling pest infestation using double stranded RNA molecules. The invention provides methods for producing transgenic cells expressing the double...
8933049 Repressor on IFN-λ promoter and siRNA against ZEB1 and BLIMP-1 to increase IFN-λ gene activity  
The present invention is directed to the identification of a novel repressor located between ˜1.2 kb to ˜1.6 kb from the translation start site of the IFN-λ1 promoter. The present invention pr...
8933046 Influenza targets  
The present invention relates to a pharmaceutical composition comprising an inhibitor of influenza virus replication. Yet another aspect is a screening method for identification of new targets for...
8933047 Poly(acrylate) polymers for in vivo nucleic acid delivery  
The present invention is directed membrane active poly(acrylate) polymers and compositions for targeted delivery of RNA interference (RNAi) polynucleotides cells in vivo. RNAi polynucleotides are...
8933050 Methods for the treatment and the diagnosis of cancer  
The present invention relates to methods for the diagnostic and the staging of cancer such as liver cancer. The present invention also relates to methods for the treatment of cancer including liver...